BackBrooklyn ImmunoTherapeutics Overview

Brooklyn ImmunoTherapeutics Accounts Payable

Brooklyn ImmunoTherapeutics's accounts payable is $8.8M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$8.80M

Peer average / median

Loading

Brooklyn ImmunoTherapeutics Accounts Payable History

Loading

Brooklyn ImmunoTherapeutics vs. peers: Accounts Payable Comparison

Loading

Brooklyn ImmunoTherapeutics Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Brooklyn ImmunoTherapeutics (BTX) FAQ

Brooklyn ImmunoTherapeutics (BTX) currently reports a accounts payable of $8.8M as of December 2025. In the prior-year period, the figure was $0. Use the charts on this page to explore Brooklyn ImmunoTherapeutics's accounts payable history and peer comparisons.

Brooklyn ImmunoTherapeutics's accounts payable changed from $0 to $8.8M (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Brooklyn ImmunoTherapeutics reported $8.8M in accounts payable as of December 2025. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $8.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Brooklyn ImmunoTherapeutics, and consider following BTX for alerts when major investors trade the stock.

Brooklyn ImmunoTherapeutics is classified in the Telecommunications sector. On accounts payable, it currently shows $8.8M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Telecommunications are usually more informative than comparing BTX with unrelated industries.